BillionToOne
Latest round
- Series D
Last raised
- Jun 2024
Total raised
- $343M
Investors
- 16
About BillionToOne
D., BillionToOne, Inc. operates as a provider of non-invasive prenatal testing through molecular counting of DNA done on blood samples. In June 2024, BillionToOne, Inc. The company provides a wide range of molecular diagnostic products, such as UNITY Screen for non-invasive prenatal screening and Northstar Select and Northstar Response for liquid biopsy. Additionally, the firm also provides services such as therapeutic response monitoring using methylation assessment.
Who invested in BillionToOne
16 investors across 5 rounds
See all investors in BillionToOne
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about BillionToOne
Who invested in BillionToOne?
BillionToOne has 16 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has BillionToOne raised?
BillionToOne has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did BillionToOne last raise money?
BillionToOne's most recent round on record is a Series D, in Jun 2024.
What does BillionToOne do?
BillionToOne is a biotechnology company.
Where is BillionToOne headquartered?
BillionToOne is headquartered in Menlo Park, US.
Which VCs invest in companies like BillionToOne?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at BillionToOne's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like BillionToOne? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.